Jason Lettmann
CIK 1688269 · CHIEF EXECUTIVE OFFICER · last filed 2026-03-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.66M
Companies
2
Total Filings
24
Lifetime Open-Market Net
-$764.9K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALXO | CHIEF EXECUTIVE OFFICER | 2,317,078 | $1.58 | $3.66M | -$5.88M | 22 | 2026-03-23 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 2,482,308 | — | — | $5.12M | 2 | 2017-06-22 |
Recent Filings · Page 2 of 3
24 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-04 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2024-08-16 | ALXO | Tax (F) | −2,191 | -$5.7K | EDGAR |
| 2024-03-18 | ALXO | Buy (P) | +4,400 | $49.8K | EDGAR |
| 2024-02-16 | ALXO | Grant (A) | +60,000 | $0 | EDGAR |
| 2023-09-12 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2023-06-22 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2022-06-16 | ALXO | Grant (A) | — | $0 | EDGAR |
| 2021-12-15 | ALXO | Sell (S) | −325,377 | -$8.90M | EDGAR |
| 2021-12-10 | ALXO | Sell (S) | −145,637 | -$4.70M | EDGAR |
| 2021-06-15 | ALXO | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.